Cargando…
Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies
Background: Methylene blue has a long history of clinical application. Thanks to phenothiazine chromophore, it has potential in photodynamic anticancer therapy. In spite of the growing body of literature that has evaluated the action of this dye on different types of cancer, the systematic understan...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568458/ https://www.ncbi.nlm.nih.gov/pubmed/37841915 http://dx.doi.org/10.3389/fphar.2023.1264961 |
_version_ | 1785119364690739200 |
---|---|
author | Taldaev, Amir Terekhov, Roman Nikitin, Ilya Melnik, Elizaveta Kuzina, Vera Klochko, Mikhail Reshetov, Igor Shiryaev, Artem Loschenov, Victor Ramenskaya, Galina |
author_facet | Taldaev, Amir Terekhov, Roman Nikitin, Ilya Melnik, Elizaveta Kuzina, Vera Klochko, Mikhail Reshetov, Igor Shiryaev, Artem Loschenov, Victor Ramenskaya, Galina |
author_sort | Taldaev, Amir |
collection | PubMed |
description | Background: Methylene blue has a long history of clinical application. Thanks to phenothiazine chromophore, it has potential in photodynamic anticancer therapy. In spite of the growing body of literature that has evaluated the action of this dye on different types of cancer, the systematic understanding of this problem is still lacking. Therefore, this systematic review was performed to study the efficacy of methylene blue in photodynamic anticancer therapy. Methods: This systematic review was carried out in accordance with the PRISMA guidelines, and the study protocol was registered in PROSPERO (CRD42022368738). Articles for the systematic review were identified through the PubMed database. SYRCLE’s risk of bias tool was used to assess the studies. The results of systematic analysis are presented as narrative synthesis. Results: Ten studies met the inclusion criteria and these full texts were reviewed. In the selected articles, the dosage of dye infusion ranged from 0.04 to 24.12 mg/kg. The effectiveness of photodynamic therapy with methylene blue against different types of cancer was confirmed by a decrease in tumor sizes in seven articles. Conclusion: The results of the systematic review support the suggestions that photodynamic therapy with methylene blue helps against different types of cancer, including colorectal tumor, carcinoma, and melanoma. In cases of nanopharmaceutics use, a considerable increase of anticancer therapy effectiveness was observed. The further research into methylene blue in photodynamic anticancer therapy is needed. Systematic Review Registration: (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=368738), identifier (CRD42022368738). |
format | Online Article Text |
id | pubmed-10568458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105684582023-10-13 Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies Taldaev, Amir Terekhov, Roman Nikitin, Ilya Melnik, Elizaveta Kuzina, Vera Klochko, Mikhail Reshetov, Igor Shiryaev, Artem Loschenov, Victor Ramenskaya, Galina Front Pharmacol Pharmacology Background: Methylene blue has a long history of clinical application. Thanks to phenothiazine chromophore, it has potential in photodynamic anticancer therapy. In spite of the growing body of literature that has evaluated the action of this dye on different types of cancer, the systematic understanding of this problem is still lacking. Therefore, this systematic review was performed to study the efficacy of methylene blue in photodynamic anticancer therapy. Methods: This systematic review was carried out in accordance with the PRISMA guidelines, and the study protocol was registered in PROSPERO (CRD42022368738). Articles for the systematic review were identified through the PubMed database. SYRCLE’s risk of bias tool was used to assess the studies. The results of systematic analysis are presented as narrative synthesis. Results: Ten studies met the inclusion criteria and these full texts were reviewed. In the selected articles, the dosage of dye infusion ranged from 0.04 to 24.12 mg/kg. The effectiveness of photodynamic therapy with methylene blue against different types of cancer was confirmed by a decrease in tumor sizes in seven articles. Conclusion: The results of the systematic review support the suggestions that photodynamic therapy with methylene blue helps against different types of cancer, including colorectal tumor, carcinoma, and melanoma. In cases of nanopharmaceutics use, a considerable increase of anticancer therapy effectiveness was observed. The further research into methylene blue in photodynamic anticancer therapy is needed. Systematic Review Registration: (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=368738), identifier (CRD42022368738). Frontiers Media S.A. 2023-09-28 /pmc/articles/PMC10568458/ /pubmed/37841915 http://dx.doi.org/10.3389/fphar.2023.1264961 Text en Copyright © 2023 Taldaev, Terekhov, Nikitin, Melnik, Kuzina, Klochko, Reshetov, Shiryaev, Loschenov and Ramenskaya. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Taldaev, Amir Terekhov, Roman Nikitin, Ilya Melnik, Elizaveta Kuzina, Vera Klochko, Mikhail Reshetov, Igor Shiryaev, Artem Loschenov, Victor Ramenskaya, Galina Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
title | Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
title_full | Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
title_fullStr | Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
title_full_unstemmed | Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
title_short | Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
title_sort | methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568458/ https://www.ncbi.nlm.nih.gov/pubmed/37841915 http://dx.doi.org/10.3389/fphar.2023.1264961 |
work_keys_str_mv | AT taldaevamir methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT terekhovroman methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT nikitinilya methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT melnikelizaveta methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT kuzinavera methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT klochkomikhail methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT reshetovigor methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT shiryaevartem methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT loschenovvictor methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies AT ramenskayagalina methyleneblueinanticancerphotodynamictherapysystematicreviewofpreclinicalstudies |